bioAffinity Technologies, Inc. (BIAF): Total Liabilities

Annual figures by period end, from SEC filings.

$3.68M
As of 2025-12-31
$3.85M
As of 2026-06-30
+47.9%
3-year compound annual growth
$13.20M2021-12-31: $13.20M2022-12-31: $1.14M2023-12-31: $3.37M2024-12-31: $3.91M2025-12-31: $3.68M$3.68M
2021-12-31 Total Liabilities (USD) 2025-12-31
Period endedTotal LiabilitiesChange YoYSource filing
2025-12-31$3.68M-5.8%2026-03-16, Balance as of period end
2024-12-31$3.91M+16.2%2026-03-16, Balance as of period end
2023-12-31$3.37M+195.6%2025-03-31, Balance as of period end
2022-12-31$1.14M-91.4%2024-04-01, Balance as of period end
2021-12-31$13.20Mn/a2023-03-31, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
bioAffinity Technologies, Inc. (BIAF)2025-12-31$3.68M-5.8%
Absci Corp (ABSI)2025-12-31$26.85M-22.1%
Foxo Technologies Inc. (FOXO)2025-12-31$33.50M-8.1%
OmniAb, Inc. (OABI)2025-12-31$33.89M-10.7%
iSpecimen Inc. (ISPC)2025-12-31$6.44M+6.7%
OneMedNet Corp (ONMD)2025-12-31$5.12M-74.0%
MaxCyte, Inc. (MXCT)2025-12-31$31.02M-6.6%
Cannabis Bioscience International Holdings, Inc. (CBIH)2025-05-31$1.20M+5.2%
NRC Health (NRC)2025-12-31$120.89M+19.4%

Compare BIAF, ABSI, FOXO, OABI side by side · Screen every company in Services-Commercial Physical & Biological Research ↗